Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Mélanie Minovès, Jean-Louis Pépin, Diane Godin-Ribuot. Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018

Member's Comments

No comment yet.

Related content which might interest you: Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 The promise of mTOR signaling as a therapeutic target for IPF Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference Year: 2020 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021 Year: 2021 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 Pathogenesis of lung cancer signalling pathways: roadmap for therapies Source: Eur Respir J 2009; 33: 1485-1497 Year: 2009 Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat Source: Annual Congress 2009 - Severe sepsis and multiple organ failure Year: 2009 The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005